Erratum to ‘Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists’ [Eur J Heart Fail 2018;20:1217–1226]

Trevisan, Marco; Deco, Pietro de; Xu, Hairong; Evans, Marie; Lindholm, Bengt; Bellocco, Rino; Bárány, Peter; Jernberg, Tomas; Lund, Lars H.; Carrero, Juan Jesús

doi:10.1002/ejhf.1367

Cited by 1 publication

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…289 MRAs carry the risk to cause hyperkalemia, although good safety profiles have been reported for kidney transplant recipients. [290][291][292] The recent FIDELIO-diabetic kidney disease study showed that the MRA finerenone versus placebo met the primary endpoint in reducing the risk of CKD progression, kidney failure, or death from renal cause, in patients with CKD and type 2 diabetes (hazard ratio 0.82). 293 Adding Daiichi-Sankyo's MRA CS-3150, known as Esaxerenone, for 12 wk to an ongoing RAAS inhibition reduced albuminuria in patients with type 2 diabetes in a phase 2 study.…”

Section: Mineralocorticoid Receptor Antagonistsmentioning

confidence: 99%

Kidney Allograft Fibrosis: Diagnostic and Therapeutic Strategies

Kramann

2021

Transplantation

View full text Add to dashboard Cite

Interstitial fibrosis with tubule atrophy (IF/TA) is the response to virtually any sustained kidney injury and correlates inversely with kidney function and allograft survival. IF/TA is driven by various pathways that include hypoxia, reninangiotensin-aldosterone system, transforming growth factor-β signaling, cellular rejection, inflammation, and others. In this review, we will focus on key pathways in the progress of renal fibrosis, diagnosis and therapy of allograft fibrosis. This review discusses the role and origin of myofibroblasts as matrix producing cells and therapeutic targets in renal fibrosis with a particular focus on renal allografts. We summarize current trends to use multiomic approaches to identify new biomarkers for IF/TA detection and to predict allograft survival. Furthermore, we review current imaging strategies that might help to identify and follow-up IF/TA complementary or as alternative to invasive biopsies. We further discuss current clinical trials and therapeutic strategies to treat kidney fibrosis. (Transplantation 2021;105: e114-e130).

show abstract